Originally dba TYRX Pharma, Inc. and renamed as TYRX Inc., as of January 2014 the firm operates as a subsidiary of Medtronic plc. Engaged in the design, development, and commercialization of resorbable polymeric biomaterials, TYRX offers absorbable and non-absorbable antibacterial envelopes/implantable devices for cardiovascular, cosmetic surgical, and other pharmaceutical applications. The company offers products to stabilize cardiac implantable devices; to reduce surgical site infection rates and treatment costs for high-risk patients. Anchored in IP licensed from Rutgers University, covering a broad range of resorbable materials and drug delivery technology as well as having Working relationships with various lare corporate entities, the firm offers PIVIT CRM, a mesh based pouch, which contains antibacterial agents to help provide protection from microbial colonization of the generator or defibrillator during and immediately after surgical implant. The company also provides AIGISRx Flat, an antibacterial product that provides protection against infections associated with implanted pacemakers and defibrillators.
